Connect your AI

Sutro Biopharma STRO Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Roivant SciencesROIV

——

Stoke Therapeutics, Inc.STOK

——

Tango TherapeuticsTNGX

——

BridgeBio PharmaBBIO

——

Septerna, Inc.SEPN

——

Other financials

Income statement

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Sutro Biopharma's proceeds from issuance of common stock relating to employee stock plans?: Sutro Biopharma (STRO) reported proceeds from issuance of common stock relating to employee stock plans of $81K in Q1 2026.
How has Sutro Biopharma's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: Sutro Biopharma's proceeds from issuance of common stock relating to employee stock plans decreased by 67.1% year-over-year, from $246K to $81K.